Catridecacog - Docslib

Sign Up
Log In
Upload

Sign Up
Log In
Upload

Home
» Tags
» Catridecacog

Catridecacog

Scientific Program Saturday, 17. July 2021 Factor VIII, Factor IX and Rare
Bebulin VH Corifact Factor VII Concentrate
Annual Report 2016
Therapeutics Advisory Group
BMJ Paediatrics Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
PRAC Draft Agenda of Meeting 08-11 March 2021
These Highlights Do Not Include All the Information Needed to Use TRETTEN Safely and Effectively
Beverly, A., Ong, G., Wilkinson, KL, Doree, C., Welton, NJ, & Estcourt, LJ
Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis
Minutes of PRAC Meeting on 06-09 July 2020
Studien Bei Seltenen Erkrankungen
Pharmaceutical Appendix to the Harmonized Tariff
Abbott Labora Tories Zambon Actelion Wockhardt Ajinomoto W a Tson Pharmaceuticals Alexion Pharmaceuticals W Arner Chilcott Aller
Comparative Analysis of Legislative Requirements About Patients’ Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
PRAC Draft Agenda of Meeting 14-17 April 2020
Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All
Lists of Medicinal Products for Rare Diseases in Europe*
Novothirteen 2500 IU for Intravenous Injection [Non-Proprietary Name] Catridecacog (Genetical Recombination) (JAN*) [Applicant] Novo Nordisk Pharma Ltd

Top View

Novothirteen, INN-Catridecacog
Stembook 2018.Pdf
English Version
INN Working Document 05.179 Update December 2010
Extract from the Clinical Evaluation Report for Catridecacog (Rys)
(INN) for Biological and Biotechnological Substances
Covering Gene Therapy, Somatic Cell Therapy), and Recombinant Proteins Other Than Monoclonal Antibodies
11-14 February 2019 PRAC Meeting Minutes
PRAC Draft Agenda of Meeting 11-14 February 2019
Challenges Facing Biosimilar Entries Into US Markets by Sarfaraz K
Orphan Drugs in Asia 2017
Medicines Not Reimbursed Through National Prices and Directly Commissioned by Nhs England
Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
Pharmaceutical Appendix to the Tariff Schedule 2
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahr 2020
CHMP Agenda of the 20-23 July 2020 Meeting
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Novothirteen, INN-Catridecacog

© 2024 Docslib.org Feedback